Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 1
2020 2
2021 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
pan-MHC and cross-Species Prediction of T Cell Receptor-Antigen Binding.
Han Y, Yang Y, Tian Y, Fattah FJ, von Itzstein MS, Hu Y, Zhang M, Kang X, Yang DM, Liu J, Xue Y, Liang C, Raman I, Zhu C, Xiao O, Dowell JE, Homsi J, Rashdan S, Yang S, Gwin ME, Hsiehchen D, Gloria-McCutchen Y, Pan K, Wu F, Gibbons D, Wang X, Yee C, Huang J, Reuben A, Cheng C, Zhang J, Gerber DE, Wang T. Han Y, et al. Among authors: gloria mccutchen y. bioRxiv [Preprint]. 2023 Dec 12:2023.12.01.569599. doi: 10.1101/2023.12.01.569599. bioRxiv. 2023. PMID: 38105939 Free PMC article. Preprint.
Immune dysregulation in cancer patients developing immune-related adverse events.
Khan S, Khan SA, Luo X, Fattah FJ, Saltarski J, Gloria-McCutchen Y, Lu R, Xie Y, Li Q, Wakeland E, Gerber DE. Khan S, et al. Among authors: gloria mccutchen y. Br J Cancer. 2019 Jan;120(1):63-68. doi: 10.1038/s41416-018-0155-1. Epub 2018 Oct 31. Br J Cancer. 2019. PMID: 30377338 Free PMC article.
Association between Antibiotic Exposure and Systemic Immune Parameters in Cancer Patients Receiving Checkpoint Inhibitor Therapy.
von Itzstein MS, Gonugunta AS, Sheffield T, Homsi J, Dowell JE, Koh AY, Raj P, Fattah F, Wang Y, Basava VS, Khan S, Park JY, Popat V, Saltarski JM, Gloria-McCutchen Y, Hsiehchen D, Ostmeyer J, Xie Y, Li QZ, Wakeland EK, Gerber DE. von Itzstein MS, et al. Among authors: gloria mccutchen y. Cancers (Basel). 2022 Mar 4;14(5):1327. doi: 10.3390/cancers14051327. Cancers (Basel). 2022. PMID: 35267634 Free PMC article.
Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors.
Ahmed M, von Itzstein MS, Sheffield T, Khan S, Fattah F, Park JY, Popat V, Saltarski JM, Gloria-McCutchen Y, Hsiehchen D, Ostmeyer J, Khan SA, Sultana N, Xie Y, Li QZ, Wakeland EK, Gerber DE. Ahmed M, et al. Among authors: gloria mccutchen y. J Immunother Cancer. 2021 Jun;9(6):e002349. doi: 10.1136/jitc-2021-002349. J Immunother Cancer. 2021. PMID: 34127546 Free PMC article.
Late-Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor-Induced Raynaud's-Like Phenomenon.
Khan S, von Itzstein MS, Lu R, Bermas BL, Karp DR, Khan SA, Fattah FJ, Park JY, Saltarski JM, Gloria-McCutchen Y, Xie Y, Li QZ, Wakeland EK, Gerber DE. Khan S, et al. Among authors: gloria mccutchen y. Oncologist. 2020 May;25(5):e753-e757. doi: 10.1634/theoncologist.2019-0666. Epub 2020 Mar 13. Oncologist. 2020. PMID: 32167195 Free PMC article.
Statin Intolerance, Anti-HMGCR Antibodies, and Immune Checkpoint Inhibitor-Associated Myositis: A "Two-Hit" Autoimmune Toxicity or Clinical Predisposition?
von Itzstein MS, Khan S, Popat V, Lu R, Khan SA, Fattah FJ, Park JY, Bermas BL, Karp DR, Ahmed M, Saltarski JM, Gloria-McCutchen Y, Xie Y, Li QZ, Wakeland EK, Gerber DE. von Itzstein MS, et al. Among authors: gloria mccutchen y. Oncologist. 2020 Aug;25(8):e1242-e1245. doi: 10.1634/theoncologist.2019-0911. Epub 2020 Jun 3. Oncologist. 2020. PMID: 32400023 Free PMC article.